Spun out of Arizona State University Biodesign Institute, Calviri Inc is developing diagnostic and therapeutic products aimed at fighting cancer by combining a unique, immunogenic source of neoantigens with a peptide array platform. The company is currently conducting clinical trials to demonstrate feasibiliity of prophylactic vaccines to rpevent cancer, developing early cancer diagnosis tests, and conducting vaccine trials aimed at reducing the time and expense of cancer treatments. The company's approach is based on three scientific insights and discoveries: Frameshift peptides' importance in developing effective vaccines and diagnostics; errors in RNA synthesis and processing by tumor cells being a better source of neoantigens than errors in DNA synthesis; and arrays of of frameshift peptides that can directly readout an individual's immune responses to tumor neoantigens.